Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Active not recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Gynecologic 4Gastrointestinal 2Dermatologic 2Thoracic 1Sarcoma 1Other hematologic neoplasm 1Lymphoid 1Head & Neck 1Genitourinary 1CNS 1Breast 1

Conditions

Stomach Neoplasms 15Colorectal Neoplasms 15Pancreatic Neoplasms 11Colonic Neoplasms 9Carcinoma, Hepatocellular 9Esophageal Neoplasms 6Rectal Neoplasms 5Colorectal Neoplasms, Hereditary Nonpolyposis 4Anus Neoplasms 4Neoplasms 3Gastrointestinal Stromal Tumors 3Gastrointestinal Neoplasms 3Gallbladder Neoplasms 3Vulvar Neoplasms 2Uterine Cervical Neoplasms 2Squamous Intraepithelial Lesions 2Peritoneal Neoplasms 2Ovarian Neoplasms 2Melanoma 2Endometrial Neoplasms 2Cholangiocarcinoma 2Bile Duct Neoplasms 2Acquired Immunodeficiency Syndrome 2Vaginal Neoplasms 1Urinary Bladder Neoplasms 1Skin Neoplasms 1Recurrence 1Pseudomyxoma Peritonei 1Prostatic Neoplasms 1Papillomavirus Infections 1

Interventions

pembrolizumab 35Nivolumab 13Cyclophosphamide 11fludarabine 9aldesleukin 9atezolizumab 7Magnetic Resonance Spectroscopy 7Carboplatin 7Specimen Handling 6Ipilimumab 6Early Intervention, Educational 6Cisplatin 6Trastuzumab 5Paclitaxel 5Methods 5Biopsy 5Bevacizumab 5durvalumab 4Vaccines 4Surveys and Questionnaires 4Radiotherapy 4Papillomavirus Vaccines 4Interleukin-2 4Docetaxel 4tisotumab vedotin 3spartalizumab 3fludarabine phosphate 3cemiplimab 3aflibercept 3Tomography, X-Ray Computed 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Uterine Cervical Neoplasms × Observation × Gastrointestinal × Clear all
NCT05179824 2025-05-06

Tempus Priority Study: A Pan-tumor Observational Study

Tempus AI

Active not recruiting
1,000 enrolled
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmSarcomaThoracic

Bile Duct Neoplasms, Urinary Bladder Neoplasms, Bone Neoplasms, Brain Neoplasms, Breast Neoplasms, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Fallopian Tube Neoplasms, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Laryngeal Neoplasms, Leukemia, Liver Neoplasms, Lung Neoplasms, Lymphoma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Skin Neoplasms, Stomach Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms

NCT03220009 2018-10-03

Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma

National Cancer Institute (NCI)

Phase 2 Withdrawn
DermatologicGastrointestinalGynecologic

Uterine Cervical Neoplasms, Esophageal Neoplasms, Melanoma, Vaginal Neoplasms, Vulvar Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡